Affluent Medical Announces Positive Results for Epygon Valve

Affluent Medical shared promising results from the Epygon biomimetic mitral valve, which showed excellent performance one year after its implantation in humans. This event marks significant progress in the field of mitral prostheses and supports the growing interest in this technology among specialists in interventional cardiology.

Published in the Journal of the American College of Cardiology, the article details the success of this innovative device in the first human implantation carried out by Professor Stefano Salizzoni and his team. Transesophageal echocardiography results after one year confirm the exceptional performance of Epygon, with no signs of mitral regurgitation or para-valvular leak.

The Epygon valve is distinguished by its ability to mimic the natural anatomy of the mitral valve, providing a less invasive treatment for patients with mitral regurgitation, a condition significantly affecting quality of life and potentially life-threatening. This development represents a significant advance in the treatment of mitral valve regurgitation, which affects approximately 160 million people worldwide.